No description available.

This study analyzed the feasibility of using gas foaming to create Poly Lactic-co-Glycolic Acid (PLGA) scaffolds for use as a substrate in bone tissue engineering and set out to determine whether the presence of osteoblasts on these scaffolds enhanced their material stiffness. The process of bone formation involves osteoblasts depositing extracellular matrix and calcifying this matrix with calcium phosphate crystals (Hasegawa et al., 2017) and pits between 30-40μm in diameter on tissue engineering scaffold surfaces have been shown to best promote osteogenic activity in the presence of bone-forming cells (Halai et al., 2014).The scaffolds were determined to contain pits within this 30-40μm range and the ability of osteoblasts to lay down and calcify extracellular matrix on gas foamed PLGA scaffolds was confirmed by the image analysis of inverted optical microscope images of Alizarin Red S-stained scaffold cryosectionsThe presence of osteogenic activity combined with the desired scaffold porosity led us to conclude that gas foaming PLGA scaffolds are a feasible method of scaffold fabrication for bone tissue engineering and allowed us to optimize the gas foaming apparatus as an instrument to be used in further bone tissue engineering experiments at California Polytechnic State University, San Luis Obispo.However, this study failed to determine whether the presence of osteoblasts improved the material stiffness of the PLGA scaffolds due to a lack of statistical significance in compression testing results.

Cardiac disease causes approximately a third of the deaths in the United States. Furthermore, most of these deaths are due to a condition termed atherosclerosis, which is a buildup of plaque in the coronary arteries, leading to occlusion of normal blood flow to the cardiac muscle. Among the methods to treat the condition, stents are devices that are used to restore normal blood flow in the atherosclerotic arteries. Before advancement can be made to these devices and changes can be tested in live models, a reliable testing method that mimics the environment of the native blood vessel is needed. Dr. Kristen Cardinal developed a tissue engineered blood vessel mimic to test intravascular devices. Among the scaffolding material used, electrospun poly (lactide-co-glycolide) (PLGA) has been used as an economic option that can be made in house. PLGA is a biodegradable co-polymer, and when electrospun, creates a porous matrix with tailorable properties. Currently, the standard PLGA electrospinning protocol produces consistent fibrous scaffolds with a mean fiber diameter of 5-6 microns. Research indicates that cell adhesion is more successful in fibrous matrices with a mean fiber diameter at the nanometer level. However, because previous work in the Tissue Engineering Laboratory at Cal Poly sought to ensure a consistent fibrous, there was no model or equation to determine how to change the electrospinning parameter settings to create scaffolds with an optimal mean fiber diameter. To fill this need, biomedical engineering senior Steffi Wong created a design of experiment to systematically approach the electrospinning variables and determine how they interacted with each other, as well as their effect on fiber diameter. The aims of this thesis were to perform the said design of experiments and determine a model to predict the resulting mean fiber diameter of a scaffold based on the electrospinning parameters as well as to determine what combination of parameters would lead to a scaffold with an optimal mean fiber diameter between 100-200 nanometers. The variables tested were solution concentration, gap distance, flow rate, and applied voltage. Each scaffold was imaged and a mean fiber diameter was calculated and used as the predicted variable in a regression analysis, with the variables indicated above as the predictors. The goal of 100-200 nanometer mean fiber diameter was not reached. The smallest mean fiber diameter calculated was 2.74 microns—half of that of the standard protocol. The regression analysis did result in a model to describe how the voltage, gap distance, and flow rate affected the fiber diameter.

No description available.

No description available.

No description available.

No description available.

No description available.

Ocular drug delivery to the posterior segment of the eye is extremely challenging. The delivery of the pharmaceuticals is made difficult by the numerous barriers that are present in the eye, as well as the isolated nature of the eye. The eye also consists of efficient drainage routes that eliminate the drug that has entered the eye successfully. Because of these reasons, drug delivery to the posterior segment of the eye is challenging and complicated. As a result, conventional eye drops are an inefficient way to deliver the pharmaceuticals to the eye as <5% of the administered dose is delivered to the anterior segment of the eye, and a negligible amount is delivered to the posterior tissues. The work presented in this thesis focuses on the design, synthesis, and characterization of the PLGA nanoparticles as a drug delivery vehicle to treat diseases associated with the posterior segment of the eye. The slow-release formulation was developed using PLGA nanoparticles and synthesized by the Double Emulsion Method (W1-O-W2). The PLGA nanoparticles were optimized by following various protocols and formulations to obtain the highest encapsulation efficacy and desired particle size range by changing the intensity of sonication, speed of ultracentrifugation, composition, and amount of the stabilizer and PLGA nanoparticles. The nanoparticles showed a 97% encapsulation efficiency with Bovine Serum Albumin (BSA) and a particle size of 201 nm. The slow-release formulation was further developed by immobilization of the particles in a thermogelling PNIPAAM scaffold. In vitro drug release results suggest that PNIPAAM containing PLGA nanoparticles produced in this work has the potential to be further developed and used as a drug delivery vehicle for the posterior segment of the eye. / Thesis / Master of Applied Science (MASc)

Yes / The aim of this study was to design a controlled release vehicle for insulin to preserve its stability and biological activity during fabrication and release. A modified, double emulsion, solvent evaporation, technique using homogenisation force optimised entrapment efficiency of insulin into biodegradable nanoparticles (NP) prepared from poly (dl-lactic-co-glycolic acid) (PLGA) and its PEGylated diblock copolymers. Formulation parameters (type of polymer and its concentration, stabiliser concentration and volume of internal aqueous phase) and physicochemical characteristics (size, zeta potential, encapsulation efficiency, in vitro release profiles and in vitro stability) were investigated. In vivo insulin sensitivity was tested by diet-induced type II diabetic mice. Bioactivity of insulin was studied using Swiss TO mice with streptozotocin-induced type I diabetic profile. Insulin-loaded NP were spherical and negatively charged with an average diameter of 200–400 nm. Insulin encapsulation efficiency increased significantly with increasing ratio of co-polymeric PEG. The internal aqueous phase volume had a significant impact on encapsulation efficiency, initial burst release and NP size. Optimised insulin NP formulated from 10% PEG–PLGA retained insulin integrity in vitro, insulin sensitivity in vivo and induced a sustained hypoglycaemic effect from 3 h to 6 days in type I diabetic mice.